Samsung Electronics Co., Ltd.

Ho Yeong Song

Seung Hyun Lee

Kyung Ah Kim

Kwang Ho Cheong

Yun Ju Jeong

Yun Jeong Song

Jae Young Choi

Ji Min Lee

Mi Young Cho

Saet Byoul Lee

Young Mi Oh

Geun Woong Kim

Hye Won Park

Yoon Aa Choi

A method for prevention or treatment of a cancer, comprising co-administering (a) an anti-c-Met antibody or an antigen-binding fragment thereof, and (b) at least one of lapatinib, regorafenib, vemurafenib or a combination thereof, to a subject in need thereof, and a pharmaceutical composition comprising (a) an anti-c-Met antibody or an antigen-binding fragment thereof, and (b) at least one of lapatinib, regorafenib, vemurafenib, or a combination thereof are provided.

Method of combination therapy using an anti-C-Met antibody

There are provided a fusion protein formed by coupling of anti-c-Met antibody and VEGF-binding fragment, a bispecific antibody comprising the fusion protein, a polynucleotide encoding the fusion protein, a transformant comprising the polynucleotide, a pharmaceutical composition comprising the bispecific antibody as an active ingredient, and a method for preparing the bispecific antibody which is targeted at c-Met and VEGF at the same time, with improved anticancer and anti-angiogenesis effects, comprising coupling an anti-c-Met antibody with a VEGF-binding fragment.

Fusion protein comprising anti-c-Met antibody and VEGF-binding fragment

Provided is a humanized and affinity-matured anti-c-Met antibody, a pharmaceutical composition including the antibody, and a method of preventing and/or treating c-Met-related disease using the antibody.

Humanized and affinity-matured anti-c-Met antibody and uses thereof

Growing community of inventors

Seongnam-si, South Korea

Ho Yeong Song